Harmony Biosciences Holdings Inc. (NASDAQ: HRMY) appointed Peter Anastasiou as chief operating officer and made changes to its board of directors.

Anastasiou previously served on Harmony's board and brings over 30 years of biotechnology experience. He most recently served as CEO of Capsida Biotherapeutics and held leadership positions at Lundbeck, including president of U.S. and Canadian operations. He resigned from the board in connection with his COO appointment.

The company appointed Troy Ignelzi to the board to fill Anastasiou's vacant seat. Ignelzi will serve the remainder of the term and stand for re-election at the 2026 annual meeting. He currently serves as CFO of Rapport Therapeutics and previously held the same role at Karuna Therapeutics, where he managed the company's IPO and financing activities.

Antonio Gracias, who has served as a director since September 2017 and chairs the compensation committee, will not seek re-election at the 2026 annual meeting. The board nominated Geno J. Germano for election at that meeting, subject to shareholder approval.

Germano has 35 years of pharmaceutical industry experience and most recently served as president and CEO of Elucida Oncology. He previously held senior roles at Pfizer, Johnson & Johnson, and Wyeth, including group president of Pfizer's global innovative pharmaceutical business.

"Peter has been an active contributor on our Board and will now bring his operational and industry experience to the Executive Team," said Jeffrey M. Dayno, president and CEO of Harmony Biosciences.

Harmony Biosciences develops therapies for patients with rare neurological diseases. The company was established in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.